Study: No benefit from intermittent therapy in prostate cancer

04/4/2013 | HealthDay News

Patients with metastatic prostate cancer who received intermittent androgen deprivation therapy had a 10% greater risk of mortality than those who got continuous hormone treatment, according to a study published in the New England Journal of Medicine. Researchers tracked more than 1,500 patients and found average survival rates of 5.8 years for the continuous therapy group and 5.1 years for the intermittent treatment group. Men who received intermittent treatment initially reported better quality of life and mental health, but those gains were lost by the end of the study.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR